 "The present choice on the future subsidies for different diabetic drugs is based on the costs of diabetes medications as well as professional treatment guidelines")
Denmark has limited GLP-1 analogs and rationalized the use of less expensive diabetic medications. The so-called GLP-1 analogues, which go by the brand names Victoza, Rybelsus, Ozempic, and Trulicity, are substantially more costly than other kinds of diabetic medications, such as metformin, SGLT-2 inhibitors, DPP-4 inhibitors, and beta-cell stimulants.
The Danish Medicines Agency has decided how much money will be subsidized going forward for non-insulin type 2 diabetic medications. The majority of diabetic medication types still receive subsidies, however there are certain modifications, and a stricter provision is added to some GLP-1 analogs. The alterations take effect on November 25, 2024.
The Danish Medicines Agency and the Medical Subsidy Board decide which therapy is most appropriate and whether the drug price, which sets the amount that the government spends on subsidies, is reasonable in relation to the therapeutic benefit when making judgments concerning medical subsidies.
Consequently, the present choice on the future subsidies for different diabetic drugs is based on the costs of diabetes medications as well as professional treatment guidelines.
For each patient group, several kinds of diabetic medicine are advised in the Danish treatment guidelines on an equal basis with GLP-1 analogs. Consequently, it makes the most sense to begin treatment with the less expensive options, and only those patients who are not responsive to these should be moved to GLP-1 medication.